JTCS Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoshimasu, T.
Right arrow Articles by Furukawa, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoshimasu, T.
Right arrow Articles by Furukawa, T.

J Thorac Cardiovasc Surg 2007;133:303-308
© 2007 The American Association for Thoracic Surgery

General Thoracic Surgery

Data acquisition for the histoculture drug response assay in lung cancer

Tatsuya Yoshimasu, MD, PhDa,*, Shoji Oura, MD, PhDa, Issei Hirai, MD, PhDa, Takeshi Tamaki, MDa, Yozo Kokawa, MD, PhDa, Kazuhito Hata, MDa, Fuminori Ohta, MDa, Rie Nakamura, MDa, Mitsumasa Kawago, MDa, Hirokazu Tanino, MD, PhDa, Yoshitaka Okamura, MD, PhDa, Tomoko Furukawa, MD, PhDb

a Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan
b Analytical Center for Medical Science, SRL, Inc, Tokyo, Japan.

Received for publication December 18, 2005; revisions received May 17, 2006; accepted for publication June 15, 2006.

* Address for reprints: Tatsuya Yoshimasu, MD, PhD, Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-8509, Japan. (Email: yositatu{at}mail.wakayama-med.ac.jp).

OBJECTIVE: Application of the histoculture drug response assay for lung cancer was investigated by using data acquired from lung cancer specimens.

METHODS: From May 1994 through February 2005, histoculture drug response assay data were obtained from 359 lung cancer specimens held in our institute. We examined chemosensitivities of the tissues to cisplatin, doxorubicin, mitomycin C, 5-fluorouracil, docetaxel, paclitaxel, etoposide, irinotecan, and gemcitabine. Cutoff inhibition rates were determined with each drug for non–small cell lung cancer and were used to calculate predictabilities for chemotherapy responses.

RESULTS: The evaluability of the histoculture drug response assay was high at 97.4%. Good predictability, including true-positive and true-negative rates of 73.2% and 100%, respectively, with an accuracy of 83.0%, was observed.

CONCLUSION: The histoculture drug response assay appears to be applicable to non–small cell lung cancer for the prediction of responses to chemotherapy.

Abbreviation and Acronyms HDRA = histoculture drug response assay; NSCLC = non–small cell lung cancer; SCLC = small cell lung cancer






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2007 by The American Association for Thoracic Surgery.